Analysts Set Masimo Co. (NASDAQ:MASI) PT at $143.57

Masimo Co. (NASDAQ:MASI) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $144.67.

A number of research firms have issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday. Piper Sandler increased their target price on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and increased their target price for the stock from $148.00 to $170.00 in a report on Monday, April 15th.

Institutional Investors Weigh In On Masimo

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Masimo by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock valued at $560,421,000 after purchasing an additional 26,473 shares in the last quarter. Capital Research Global Investors raised its stake in Masimo by 6.4% during the 4th quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider’s stock worth $265,972,000 after acquiring an additional 136,617 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Masimo by 6.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider’s stock worth $188,393,000 after acquiring an additional 93,861 shares in the last quarter. Farallon Capital Management LLC raised its stake in Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Finally, Schroder Investment Management Group raised its stake in Masimo by 59.6% during the 4th quarter. Schroder Investment Management Group now owns 877,539 shares of the medical equipment provider’s stock worth $102,856,000 after acquiring an additional 327,863 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Stock Performance

NASDAQ:MASI opened at $126.87 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31. The stock has a market capitalization of $6.75 billion, a P/E ratio of 86.31 and a beta of 0.97. The company has a 50 day moving average price of $118.86 and a 200 day moving average price of $127.82. Masimo has a fifty-two week low of $75.22 and a fifty-two week high of $153.93.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The firm had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company posted $0.62 EPS. Equities research analysts forecast that Masimo will post 3.63 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.